Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Senseonics Stock Skyrocketed Today

By Joe Tenebruso - Jun 4, 2021 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare specialist's innovative sensors could help people with diabetes better manage their health.

What happened

Shares of Senseonics Holdings (SENS 4.70%) soared 43% on Friday after the medical technology company announced promising clinical trial results from a study of its implantable continuous glucose monitoring (CGM) system. 

So what

A study designed to evaluate the Eversense CGM system in diabetes patients over a 180-day period demonstrated that the confirmed hypoglycemic-alert detection rate was 93% for the system's primary sensor and 94% for its secondary sensor. 

A person is pointing to an upwardly sloping stock chart.

Senseonics Holdings' stock price surged on Friday. Image source: Getty Images.

Moreover, there were no serious adverse events reported during the study among its 181 participants. All of the sensors were successfully removed, with only 1.1% of patients experiencing a mild infection at the procedure site.

"The accuracy profile demonstrated by Eversense in the Promise study validates the role that long-term implantable CGM systems can play in helping people manage their glucose levels," Dr. Satish Garg, study principal investigator, said in a press release.

Now what 

Senseonics' Eversense CGM system helps people with diabetes track and manage their glucose levels. A medical professional inserts a sensor subcutaneously in a patient's upper arm. A smart device that's worn over the sensor then sends data to a mobile app that displays glucose values and alerts. It's an innovative design -- one that could help to make diabetes an easier condition to live with.

"The value of CGM for patients with diabetes, especially those requiring insulin, is unquestioned," Dr. Garg said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Senseonics Holdings, Inc. Stock Quote
Senseonics Holdings, Inc.
SENS
$2.23 (4.70%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.